GE HealthCare begins phase 2/3 trial for manganese-based MRI contrast agent

April 23, 2026 7:29 AM

GE HealthCare Technologies Inc. (NASDAQ: GEHC) announced the first patient has been dosed in its Phase 2/3 LUMINA clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found